Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

The way of SARS-CoV-2 vaccine development: success and challenges
Yetian Dong, Tong Dai, Bin Wang, et al.
Signal Transduction and Targeted Therapy (2021) Vol. 6, Iss. 1
Open Access | Times Cited: 50

Showing 1-25 of 50 citing articles:

Efficacy of mRNA, adenoviral vector, and perfusion protein COVID-19 vaccines
Mohammad Reza Zinatizadeh, Peyman Kheirandish Zarandi, Maryam Zinatizadeh, et al.
Biomedicine & Pharmacotherapy (2021) Vol. 146, pp. 112527-112527
Open Access | Times Cited: 42
Principles for optimization and validation of mRNA lipid nanoparticle vaccines against COVID-19 using 3D bioprinting
Massimiliano Papi, Daniela Pozzi, Valentina Palmieri, et al.
Nano Today (2022) Vol. 43, pp. 101403-101403
Open Access | Times Cited: 34
Impairment of SARS-CoV-2 spike glycoprotein maturation and fusion activity by nitazoxanide: an effect independent of spike variants emergence
Anna Riccio, Silvia Santopolo, Antonio Rossi, et al.
Cellular and Molecular Life Sciences (2022) Vol. 79, Iss. 5
Open Access | Times Cited: 29
The Role of Cellular Immunity in the Protective Efficacy of the SARS-CoV-2 Vaccines
Zhongjie Sun, Tingxin Wu, Huangfan Xie, et al.
Vaccines (2022) Vol. 10, Iss. 7, pp. 1103-1103
Open Access | Times Cited: 24
Intranasal trimeric sherpabody inhibits SARS-CoV-2 including recent immunoevasive Omicron subvariants
Anna R. Mäkelä, Hasan Uğurlu, Liina Hannula, et al.
Nature Communications (2023) Vol. 14, Iss. 1
Open Access | Times Cited: 12
The mechanisms of immune response and evasion by the main SARS-CoV-2 variants
Qiuli Chen, Jiawei Zhang, Peter Wang, et al.
iScience (2022) Vol. 25, Iss. 10, pp. 105044-105044
Open Access | Times Cited: 21
The next major emergent infectious disease: reflections on vaccine emergency development strategies
Yu Bai, Qian Wang, Mingchen Liu, et al.
Expert Review of Vaccines (2022) Vol. 21, Iss. 4, pp. 471-481
Open Access | Times Cited: 18
A comparison between SARS-CoV-1 and SARS-CoV2: an update on current COVID-19 vaccines
Gelareh Abdolmaleki, Mina Taheri, Sarina Paridehpour, et al.
DARU Journal of Pharmaceutical Sciences (2022) Vol. 30, Iss. 2, pp. 379-406
Open Access | Times Cited: 18
Combination of Isothermal Recombinase-Aided Amplification and CRISPR-Cas12a-Mediated Assay for Rapid Detection of Major Severe Acute Respiratory Syndrome Coronavirus 2 Variants of Concern
Hongqing Lin, Yuanhao Liang, Lirong Zou, et al.
Frontiers in Microbiology (2022) Vol. 13
Open Access | Times Cited: 16
Persistence of Naturally Acquired and Functional SARS-CoV-2 Antibodies in Blood Donors One Year after Infection
Verena Nunhofer, Lisa Weidner, Alexandra Domnica Hoeggerl, et al.
Viruses (2022) Vol. 14, Iss. 3, pp. 637-637
Open Access | Times Cited: 14
Colonization of nasal cavities by Staphylococcus epidermidis mitigates SARS‐CoV‐2 nucleocapsid phosphoprotein‐induced interleukin (IL)‐6 in the lung
Ming‐Shan Kao, Jen‐Ho Yang, Arun Balasubramaniam, et al.
Microbial Biotechnology (2022) Vol. 15, Iss. 7, pp. 1984-1994
Open Access | Times Cited: 13
The FDA-approved drug nitazoxanide is a potent inhibitor of human seasonal coronaviruses acting at postentry level: effect on the viral spike glycoprotein
Sara Piacentini, Anna Riccio, Silvia Santopolo, et al.
Frontiers in Microbiology (2023) Vol. 14
Open Access | Times Cited: 7
Nasal irrigation efficiently attenuates SARS-CoV-2 Omicron infection, transmission and lung injury in the Syrian hamster model
Lunzhi Yuan, Huachen Zhu, Ming Zhou, et al.
iScience (2022) Vol. 25, Iss. 12, pp. 105475-105475
Open Access | Times Cited: 10
The importance of equally accessible genomic surveillance in the age of pandemics
Safia Zeghbib, Gábor Kemenesi, Ferenc Jakab
Biologia Futura (2023) Vol. 74, Iss. 1-2, pp. 81-89
Open Access | Times Cited: 5
A Potent Neutralizing Nanobody Targeting the Spike Receptor-Binding Domain of SARS-CoV-2 and the Structural Basis of Its Intimate Binding
Jing Yang, Sheng Lin, Honglu Sun, et al.
Frontiers in Immunology (2022) Vol. 13
Open Access | Times Cited: 9
Nanomaterials as a Versatile Tool for COVID-19 Treatment
Safieh Zeinali, Zeinab Moafian, Rabia Arshad, et al.
BioNanoScience (2024) Vol. 14, Iss. 4, pp. 3950-3987
Closed Access | Times Cited: 1
A comprehensive immune repertoire signature distinguishes pulmonary infiltration in SARS-CoV-2 Omicron variant infection
Xuechuan Li, Hongyi Zhu, Peipei Xu, et al.
Frontiers in Immunology (2024) Vol. 15
Open Access | Times Cited: 1
Immunosuppressive treatments selectively affect the humoral and cellular response to SARS-CoV-2 in vaccinated patients with vasculitis
Sara Monti, Chiara Fornara, Paolo Delvino, et al.
Lara D. Veeken (2022) Vol. 62, Iss. 2, pp. 726-734
Open Access | Times Cited: 8
Comparison between Neutralization Capacity of Antibodies Elicited by COVID-19 Natural Infection and Vaccination in Indonesia: A Prospective Cohort
Sitti Nurisyah, Mitsuhiro Iyori, Ammar Abdurrahman Hasyim, et al.
Antibodies (2023) Vol. 12, Iss. 3, pp. 60-60
Open Access | Times Cited: 4
Humoral Immune Response Diversity to Different COVID-19 Vaccines: Implications for the “Green Pass” Policy
Immacolata Polvere, Alfredina Parrella, Lucrezia Zerillo, et al.
Frontiers in Immunology (2022) Vol. 13
Open Access | Times Cited: 7
A Heterologous Challenge Rescues the Attenuated Immunogenicity of SARS-CoV-2 Omicron BA.1 Variant in Syrian Hamster Model
Jian Ma, Xuan Liu, Ming Zhou, et al.
Journal of Virology (2023) Vol. 97, Iss. 2
Open Access | Times Cited: 3
Novel Inhibitory Role of Fenofibric Acid by Targeting Cryptic Site on the RBD of SARS-CoV-2
Jianxiang Huang, Chun Chan, Ruhong Zhou
Biomolecules (2023) Vol. 13, Iss. 2, pp. 359-359
Open Access | Times Cited: 3
Impairment of SARS-CoV-2 spike-glycoprotein maturation and fusion-activity by nitazoxanide: an effect independent of spike variants emergence
Anna Riccio, Silvia Santopolo, Antonio Rossi, et al.
bioRxiv (Cold Spring Harbor Laboratory) (2021)
Open Access | Times Cited: 8
Validation of the GSP®/DELFIA® Anti-SARS-CoV-2 IgG Kit Using Dried Blood Samples for High-Throughput Serosurveillance and Standardized Quantitative Measurement of Anti-Spike S1 IgG Antibody Responses Post-Vaccination
Ilaria Cicalini, Piero Del Boccio, Mirco Zucchelli, et al.
Vaccines (2022) Vol. 10, Iss. 4, pp. 514-514
Open Access | Times Cited: 5
The Emergence of SARS-CoV-2 Variants With a Lower Antibody Response: A Genomic and Clinical Perspective
Suvro Biswas, Shafi Mahmud, Mohasana Akter Mita, et al.
Frontiers in Medicine (2022) Vol. 9
Open Access | Times Cited: 5
Page 1 - Next Page

Scroll to top